Roche Tempium Discontinued Following Abnormal Liver Tests In Phase III
Executive Summary
Elevated bilirubin and liver transaminase levels in a Phase III trial led to discontinuation of development of Roche's Tempium (lazabemide). The company announced the halt of the Alzheimer's therapy program on Sept. 14.
You may also be interested in...
SB Relinquishes Frovatriptan Royalties As Final Step In Antitrust Review
SmithKline Beecham will receive up to $25 mil. in payments from Vernalis in exchange for surrendering its 7% royalty on the pending antimigraine agent Miguard (frovatriptan).
SB Relinquishes Frovatriptan Royalties As Final Step In Antitrust Review
SmithKline Beecham will receive up to $25 mil. in payments from Vernalis in exchange for surrendering its 7% royalty on the pending antimigraine agent Miguard (frovatriptan).
Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do
Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: